Format

Send to

Choose Destination
NPJ Breast Cancer. 2018 Mar 12;4:6. doi: 10.1038/s41523-018-0057-7. eCollection 2018.

An assessment of neuronal calcium sensor-1 and response to neoadjuvant chemotherapy in breast cancer patients.

Author information

1
1Department of Pathology, Yale School of Medicine, New Haven, CT USA.
2
3Department of Thoracic/ Head & Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX USA.
3
2Department of Pharmacology, Yale School of Medicine, New Haven, CT USA.

Abstract

Neuronal calcium sensor-1 (NCS-1) has been identified as a binding partner of the taxane, paclitaxel. Our previous study showed that overexpression of NCS-1 increased the efficacy of paclitaxel in vitro, but was associated with poor clinical outcome. Here, we determine if NCS-1 expression is associated with pathological complete response (pCR) to taxane-based neoadjuvant chemotherapy in 105 pre-treatment breast cancer biopsies. Elevated expression of NCS-1 was found to be positively associated with pCR. These results suggest that NCS-1 may be a predictive biomarker for response to taxane-based neoadjuvant chemotherapy in breast cancer.

Conflict of interest statement

In the last 24 months D.L.R. has been a consultant to Astra Zeneca, Agendia, Bethyl Labs, Biocept, BMS, Cell Signaling Technology, Cepheid, ClearSight, Genoptix/Novartis, Merck, OptraScan, Perkin Elmer, and Ultivue. D.L.R. has received grant funding from Cepheid, Genoptix, Gilead Sciences, Pierre Fabre, Perkin Elmer and Nantomics. None of these interactions are related to this work. The remaining authors declare no competing interests.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center